Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-722 · 5 trials · 2 indications
Cmax of ABBV-722
Tmax of ABBV-722
AUCt of ABBV-722
AUCinf of ABBV-722
β of ABBV-722
t1/2 of ABBV-722
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax,ss of ABBV-722
Tmax of ABBV-722
AUCtau,ss of ABBV-722
Ctrough,ss of ABBV-722
Cmax,ss of Upadacitinib
Tmax of Upadacitinib
AUCtau,ss of Upadacitinib
Ctrough,ss of Upadacitinib
Safety evaluations will include AE monitoring, vital sign measurements (including orthostatic blood pressure and pulse rate), ECG variables, and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration. Clinically significant abnormal changes in physical examination findings will be reported as AEs.
Cmax of ABBV-722.
AUCt of ABBV-722.
AUCinf of ABBV-722
Ctrough of ABBV-722.
AUC from AUCtau following the first and last doses of ABBV-722.
Beta of ABBV-722.
Dose normalized Cmax.
Dose normalized AUCs.
| Arm | Type | Description |
|---|---|---|
| Period 1 & 2 | EXPERIMENTAL | In Period 1, participants will receive a single dose of ABBV-722. In Period 2, participants will receive multiple daily doses of Itraconazole and a single dose of ABBV-722. |
| Period 1: Group 1 | EXPERIMENTAL | Participants will receive multiple doses of Upadacitinib |
| Period 1: Group 2 | EXPERIMENTAL | Participants will receive multiple doses of Upadacitinib |
| Period 2: Group 1 | EXPERIMENTAL | Participants will receive multiple doses of ABBV-722 |
| Period 2: Group 2 | EXPERIMENTAL | Participants will receive multiple doses of ABBV-722 |
| Period 3: Group 1 | EXPERIMENTAL | Participants will receive multiple doses of ABBV-722 and Upadacitinib |
| Period 3: Group 2 | EXPERIMENTAL | Participants will receive multiple doses of ABBV-722 and Upadacitinib |
| Period 1: Single Dose A | EXPERIMENTAL | Single dose will be administered under fasted conditions |
| Period 2: Single Dose A | EXPERIMENTAL | Single dose will be administered under fed (high-fat meal) conditions |
| Period 3: Single Dose B | EXPERIMENTAL | Single dose will be administered under fasted conditions |
| Part 1: Group 1 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose A or placebo. |
| Part 1: Group 2 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose B or placebo. |
| Part 1: Group 3 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose C or placebo. |
| Part 1: Group 4 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose TBD or placebo. |
| Part 1: Group 5 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose TBD or placebo. |
| Part 2: Group 6 | EXPERIMENTAL | Participants who are Han Chinese will receive a single dose of ABBV-722 Dose D. |
| Part 2: Group 7 | EXPERIMENTAL | Participants who are Japanese will receive a single dose of ABBV-722 Dose D. |
| Part 3: Group 8 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose E or placebo for 14 days. |
| Part 3: Group 9 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose F or placebo for 14 days. |
| Part 3: Group 10 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose A or placebo for 14 days. |
| Part 3: Group 11 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose G or placebo for 14 days. |
| Part 3: Group 12 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose TBD or placebo for 14 days. |
| Name | Type | Description |
|---|---|---|
| ABBV-722 | DRUG | Oral Tablet |
| Itraconazole | DRUG | Oral Capsule |
| Midazolam | DRUG | Oral Solution |
| Metformin | DRUG | Oral Tablet |
| Digoxin | DRUG | Oral Tablet |
| Pitavastatin | DRUG | Oral Tablet |
| Sitagliptin | DRUG | Oral Tablet |
| Upadacitinib | DRUG | Oral |
| Placebo | DRUG | Oral Capsule |
Inclusion Criteria: * Laboratory values meet the criteria specified in the protocol. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG). Exclusion Criteria: * History of an...
ABBV-722 is an investigational small molecule being developed by AbbVie Inc. It is in Phase 1 clinical development, and its therapeutic indications have not been disclosed. All of its clinical testing to date has been conducted in healthy adult volunteers rather than in patients with a specific disease.
ABBV-722 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the Phase 1 clinical program evaluating the compound in healthy adult participants in the United States.
ABBV-722 is in Phase 1 clinical development. Five Phase 1 trials have been completed, and none are currently active. The studies enrolled a total of 146 participants, all healthy adults, and the program has not yet advanced into later-stage testing in patients.
ABBV-722 has been studied in five completed Phase 1 trials, including NCT07599761, which assessed the effect of itraconazole on ABBV-722; NCT07567781, which assessed ABBV-722's effect on midazolam, digoxin, pitavastatin, metformin, and sitagliptin levels; NCT07425899, which evaluated ABBV-722 with upadacitinib; and NCT07361367, a food-effect tablet study.
Yes. The ABBV-722 Phase 1 program includes randomized, double-blind, controlled trials. The studies were conducted in healthy adult volunteers in the United States, with participants aged 18 years and older of any sex. Total enrollment across the completed trials was 146 participants.
The therapeutic indications for ABBV-722 have not been disclosed. The compound is an investigational small molecule in Phase 1 development, and its completed trials were conducted in healthy adult volunteers to evaluate safety, drug interactions, and how the body processes the drug rather than to treat a specific disease.